+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-05-18Number of Pages: 192

Hospital Pharmaceuticals Market (Therapeutic Class and Indication - Cardiology, Oncology, Nephrology and Urology, Neurology, Pain, and Infection) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

Pharmaceutical drugs are sold through various channels such as retail, mail orders, clinics and hospitals. This report on the global hospital pharmaceuticals market analyses the current and future prospects of the market specifically pertaining to drugs sold in hospital settings. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a robust combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ million for each segment for the period from 2013 to 2023, considering the macro and micro environmental factors. Growth rates for each segment within the global teleradiology market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

Market revenue in terms of US$ Mn for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all the segments, considering 2014 as the base year. Global hospital pharmaceutical drugs market is segmented according to major therapeutic areas, which include: cardiology, oncology, nephrology and urology, neurology, pain and infection. Market for these major therapeutic areas has been further assessed according to drug classes. Cardiology segment is further divided into anti-hypertensive drugs, dyslipidemia drugs, and others (ACE inhibitors, angiotensin receptor blockers, anticoagulants). Oncology segment is further segmented into immunomodulating agents, alkylating agents, anti-metabolites, hormonal agents, and miscellaneous drugs. Nephrology and urology segment is further divided into diuretic drugs, anti-hypertensive agents, phosphate binders, anti-cholinergic agents and 5-alpha-reductase inhibitors. Neurology segment is divided into anti-anxiety, anti-migraine, anti-depressant and anti-psychotic drugs. Market for pain management drugs has been divided into anti-convulsant drugs, anesthetics, nonsteroidal anti-inflammatory drugs (NSAID), opioids, and non-narcotic analgesic drugs. Similarly anti-infective drugs market has been segmented into anti-bacterial drugs, anti-viral drugs, anti-fungal drugs and anti-parasite drugs. The report also provides a detailed list of potential phase III candidates for each of the therapeutic areas.

The market has been further studied from the point of view of major diseases in these therapeutic areas. Thus the cardiology market has been studied considering coronary heart diseases, stroke, high blood pressure (hypertension), heart failure and other cardiovascular diseases. Oncology drugs market has been studied for lung cancer, breast cancer, colorectal cancer, prostate cancer, and others. Nephrology and urology drugs market is studied for acute kidney failure, chronic kidney diseases, glomerular diseases, diabetes and other diseases. Neurology market has been studied for epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke and other diseases.

Market for pain has been studied for neuropathic pain, fibromyalgia, osteoarthritis, rheumatoid arthritis, cancer pain and others. The infection market is studied for major infectious disease such as tuberculosis, pneumonia, hepatitis A, hepatitis B, Candida infections, fungal meningitis, shigellosis, amoebiasis and other infections. The report also provides insights for various branded and blockbuster drugs under various therapeutic drug class. Moreover, the report also provides the approval date and the patent expiry for major drugs in the event impact analysis section.

Additionally, the report contains market attractiveness analysis by geography and competitive landscape by key players. The market attractiveness analysis explains the intensity of competition in the market in different geographies. The competitive scenario between different market players is evaluated through market share analysis. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Geographically, this market has been segmented into four regions: North America, Europe, Asia-Pacific, Latin America, and Rest of the World (RoW). In addition the regions have been further segmented by major countries from each region, which include the U.S, Canada, Japan, China, U.K., Germany and Brazil. The report also profiles major players in the hospital pharmaceuticals market based on various attributes such as company overview, financial overview, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Novartis, and Pfizer, Inc.

The global hospital pharmaceuticals market has been segmented as follows: 

Global Hospital Pharmaceuticals Market, by Therapeutic Class

  • Cardiology
    • Anti-hypertensives
    • Dyslipidemia drugs
    • Others
  • Oncology
    • Alkylating Agents
    • Anti-metabolites
    • Hormonal Agents
    • Immunomodulating Agents
    • Miscellaneous Drugs
  • Nephrology and Urology
    • Diuretic Agents
    • Anti-hypertensive Agents
    • Phosphate Binders
    • Anticholinergic Drugs
    • 5-Alpha Reductase Inhibitors
  • Neurology
    • Anti-anxiety Agents
    • Anti-migraine Drugs
    • Antidepressant Drugs
    • Anti-psychotic Drugs
  • Pain
    • Anticonvulsant Drugs
    • Anesthetic Drugs
    • Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Opioids
    • Non-narcotics Analgesic Drugs
  • Infection
    • Antibacterial Drugs
    • Antiviral Drugs
    • Antifungal Drugs
    • Antiparasite Drugs

Global Hospital Pharmaceuticals Market, by Indication

  • Cardiology
    • Coronary Heart Diseases
    • Stroke
    • High Blood Pressure
    • Heart Failure
    • Others
  • Oncology
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Others
  • Nephrology and Urology
    • Acute Kidney Failure
    • Chronic Kidney Diseases
    • Glomerular Diseases
    • Diabetes
    • Others
  • Neurology
    • Epilepsy
    • Alzheimer’s Disease
    • Parkinson’s Disease
    • Multiple Sclerosis
    • Others
  • Pain
    • Neuropathic Pain
    • Fibromyalgia
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Cancer Pain
  • Infection
    • Tuberculosis
    • Pneumonia
    • Hepatitis A
    • Hepatitis B
    • Candida Infection
    • Fungal Meningitis
    • Shigellosis
    • Amoebiasis
    • Other

Global Hospital Pharmaceuticals Market, by Geography

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • Rest of APAC
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Rest of the World

Table of Content

1. Preface
    1.1. Report Description
    1.2. Market Segmentation
    1.3. Research Methodology
    1.4. Assumptions

2. Executive Summary
    2.1. Global Hospital Pharmaceuticals Market Revenue, by Therapeutic Area, 2014 & 2023 (US$ Mn)
    2.2. Global Hospital Pharmaceuticals Market Revenue, by Countries, 2014 (US$ Mn)
    2.3. Global Hospital Pharmaceuticals Market Revenue, by Geography, 2014 & 2023 (US$ Mn)
    2.4. Global Hospital Pharmaceuticals Market, 2014 & 2023: Market Snapshot 

3. Global Hospital Pharmaceuticals Market – Industry Analysis
    3.1. Introduction
    3.2. Market Dynamics
          3.2.1. Drivers
                  3.2.1.1. Driver 1 - Increased emergency department visits drive demand for hospital drugs
                  3.2.1.2. Driver 2 - Rise in spending on medicines
                  3.2.1.3. Driver 3 - High prevalence of diseases across the world
                  3.2.1.4. Driver 4- Trend towards increase in use of telemedicine technology by hospitals
          3.2.2. Restraints
                  3.2.2.1. Restraint 1- Patent Expirations of Blockbuster Drugs
                  3.2.2.2. Restraint 2- Shift toward use of home health care services
          3.2.3. Opportunities
                  3.2.3.1. Opportunity 1- Extensive R&D activities lead to introduction of new drugs in market
                  3.2.3.2. Opportunity 2- Increasing no. of hospitals in developing economies
    3.3. Event Impact Analysis
    3.4. Value Chain Analysis
    3.5. Market Attractiveness Analysis: Global Hospital Pharmaceuticals Market
    3.6. Market Share Analysis: Global Hospital Pharmaceuticals Market, by Key Players, 2013 (Value %)

4. Market Segmentation – By Product Type
    4.1. Introduction
          4.1.1. Global Hospital Pharmaceuticals Market Revenue, by Major Therapeutic Area, (U.S. $ Mn), 2013-2023
    4.2. Cardiology
          4.2.1. Introduction
          4.2.2. Global Cardiology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.2.3. Global Antihypertensive Drugs Market Revenue, (US$ Mn), 2013-2023
          4.2.4. Global Dyslipidemia Drugs Market Revenue, (US$ Mn), 2013-2023
          4.2.5. Global Other Cardiology Drugs Market Revenue, (US$ Mn), 2013-2023
    4.3. Oncology
          4.3.1. Introduction
          4.3.2. Global Oncology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.3.3. Global Immunomodulating Agents Market Revenue, (US$ Mn), 2013-2023
          4.3.4. Global Alkylating Agents Market Revenue, (US$ Mn), 2013-2023
          4.3.5. Global Anti-metabolites Market Revenue, (US$ Mn), 2013-2023
          4.3.6. Global Hormonal Agents Market Revenue, (US$ Mn), 2013-2023
          4.3.7. Global Miscellaneous Oncology Drugs Market Revenue, (US$ Mn), 2013-2023
    4.4. Nephrology and Urology
          4.4.1. Introduction
          4.4.2. Global Nephrology and Urology Hospital Pharmaceuticals Market Revenue, by Therapeutic Classs, (US$ Mn), 2013-2023
          4.4.3. Global Diuretics Market Revenue, (US$ Mn), 2013-2023
          4.4.4. Global Anti-Hypertensives Market Revenue, (US$ Mn), 2013-2023
          4.4.5. Global Phosphate Binders Market Revenue, (US$ Mn), 2013-2023
          4.4.6. Global Anti-Cholinergics Market Revenue, (US$ Mn), 2013-2023
          4.4.7. Global 5-alpha-reductase Inhibitors Market Revenue, (US$ Mn), 2013-2023
    4.5. Neurology
          4.5.1. Introduction
          4.5.2. Global Neurology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.5.3. Global Diuretics Market Revenue, (US$ Mn), 2013-2023
          4.5.4. Global Anti-Anxiety Market Revenue, (US$ Mn), 2013-2023
          4.5.5. Global Anti-Migraine Market Revenue, (US$ Mn), 2013-2023
          4.5.6. Global Anti-Depressant Market Revenue, (US$ Mn), 2013-2023
          4.5.7. Global Anti-Psychotics Market Revenue, (US$ Mn), 2013-2023
    4.6. Pain
          4.6.1. Introduction
          4.6.2. Global Pain Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.6.3. Global Anti-Convulsants Market Revenue, (US$ Mn), 2013-2023
          4.6.4. Global Anesthetics Market Revenue, (US$ Mn), 2013-2023
          4.6.5. Global NSAID's Market Revenue, (US$ Mn), 2013-2023
          4.6.6. Global Opioids Market Revenue, (US$ Mn), 2013-2023
          4.6.7. Global Non-Narcotic Agents Market Revenue, (US$ Mn), 2013-2023
    4.7. Infection
          4.7.1. Introduction
          4.7.2. Global Infection Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.7.3. Global Anti-Bacterial Drugs Market Revenue, (US$ Mn), 2013-2023
          4.7.4. Global Anti-Viral Drugs Market Revenue, (US$ Mn), 2013-2023
          4.7.5. Global Anti-Fungal Drugs Market Revenue, (US$ Mn), 2013-2023
          4.7.6. Global Anti-Parasite Drugs Market Revenue, (US$ Mn), 2013-2023

5. Market Segmentation – By Indication
    5.1. Introduction
          5.1.1. Global Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
    5.2. Cardiology
          5.2.1. Global Cardiology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
          5.2.2. Global Coronary Heart Disease Market Revenue, (US$ Mn), 2013-2023
          5.2.3. Global Stroke Market Revenue, (US$ Mn), 2013-2023
          5.2.4. Global High Blood Pressure Market Revenue, (US$ Mn), 2013-2023
          5.2.5. Global Heart Failure Market Revenue, (US$ Mn), 2013-2023
          5.2.6. Global Other Cardiology Indications Market Revenue, (US$ Mn), 2013-2023
    5.3. Oncology
          5.3.1. Global Oncology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
          5.3.2. Global Lung Cancer Market Revenue, (US$ Mn), 2013-2023
          5.3.3. Global Breast Cancer Market Revenue, (US$ Mn), 2013-2023
          5.3.4. Global Colorectal Cancer Market Revenue, (US$ Mn), 2013-2023
          5.3.5. Global Prostate Cancer Market Revenue, (US$ Mn), 2013-2023
          5.3.6. Global Other Oncology Indications Market Revenue, (US$ Mn), 2013-2023
    5.4. Nephrology and Urology
          5.4.1. Global Nephrology and Urology Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
          5.4.2. Global Acute Kidney Failure Market Revenue, (US$ Mn), 2013-2023
          5.4.3. Global Chronic Kidney Diseases Market Revenue, (US$ Mn), 2013-2023
          5.4.4. Global Glomerular Diseases Market Revenue, (US$ Mn), 2013-2023
          5.4.5. Global Diabetes Market Revenue, (US$ Mn), 2013-2023
          5.4.6. Global Other Nephrology and Urology Indications Market Revenue, (US$ Mn), 2013-2023
    5.5. Neurology
          5.5.1. Global Neurology Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
          5.5.2. Global Epilepsy Market Revenue, (US$ Mn), 2013-2023
          5.5.3. Global Alzheimer's Disease Market Revenue, (US$ Mn), 2013-2023
          5.5.4. Global Parkinson's Disease Market Revenue, (US$ Mn), 2013-2023
          5.5.5. Global Multiple Sclerosis Market Revenue, (US$ Mn), 2013-2023
          5.5.6. Global Stroke Market Revenue, (US$ Mn), 2013-2023
          5.5.7. Global Other Neurology Indications Market Revenue, (US$ Mn), 2013-2023
    5.6. Pain
          5.6.1. Global Pain Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
          5.6.2. Global Neuropathic Pain Market Revenue, (US$ Mn), 2013-2023
          5.6.3. Global Fibromyalgia Market Revenue, (US$ Mn), 2013-2023
          5.6.4. Global Osteoarthritis Market Revenue, (US$ Mn), 2013-2023
          5.6.5. Global Rheumatoid Arthritis Market Revenue, (US$ Mn), 2013-2023
          5.6.6. Global Cancer Pain Market Revenue, (US$ Mn), 2013-2023
          5.6.7. Global Other Pain Indications Market Revenue, (US$ Mn), 2013-2023
    5.7. Infection
          5.7.1. Global Infection Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
          5.7.2. Global Tuberculosis Market Revenue, (US$ Mn), 2013-2023
          5.7.3. Global Pneumonia Market Revenue, (US$ Mn), 2013-2023
          5.7.4. Global Hepatitis A Market Revenue, (US$ Mn), 2013-2023
          5.7.5. Global Hepatitis B Market Revenue, (US$ Mn), 2013-2023
          5.7.6. Global Candida Infection Market Revenue, (US$ Mn), 2013-2023
          5.7.7. Global Fungal Meningitis Market Revenue, (US$ Mn), 2013-2023
          5.7.8. Global Shigellosis Market Revenue, (US$ Mn), 2013-2023
          5.7.9. Global Amoebiasis Market Revenue, (US$ Mn), 2013-2023
          5.7.10. Global Other Infection Indications Market Revenue, (US$ Mn), 2013-2023

6. Market Segmentation – By Geography
    6.1. Global Hospital Pharmaceuticals Market Revenue, by Geography, (US$ Mn), 2013-2023
    6.2. North America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.2.1. U.S. Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.2.2. Canada Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
    6.3. Europe Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.3.1. U.K. Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.3.2. Germany Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.3.3. Rest of Europe Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
    6.4. Asia Pacific Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.4.1. China Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.4.2. Japan Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.4.3. Rest of Asia Pacific Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
    6.5. Latin America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.5.1. Brazil Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.5.2. Mexico Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.5.3. Rest of Latin America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
    6.6. Rest of the World Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023

7. Company Profiles
    7.1. AztraZeneca plc
    7.2. Bayer AG
    7.3. Bristol-Myers Squibb Company
    7.4. Eli Lilly and Company
    7.5. GlaxoSmithKline plc
    7.6. Johnson and Johnson
    7.7. Merck and Co., Inc.
    7.8. Novartis AG
    7.9. Pfizer, Inc.
    7.10. Sanofi-Aventis

List of Figures

FIG. 1 Global Teleradiology Market Share, by Geography, 2014 (Value %)
FIG. 2 Hospital Pharmaceuticals Market Segmentation
FIG. 3 Global Hospital Pharmaceuticals Market, by Therapeutic Area, 2014 & 2023 (US$ Million)
FIG. 4 Global Hospital Pharmaceuticals Market Revenue, by Countries, 2014 (US$ Mn)
FIG. 5 Comparative Analysis: Global Hospital Pharmaceuticals Market, by Geography, 2014 & 2023 (Value %)
FIG. 6 Global Hospital Pharmaceutical Market, Value Chain Analysis
FIG. 7 Market Attractiveness Analysis: Global Hospital Pharmaceutical Market, by Geography, 2014
FIG. 8 Market Share Analysis: Global Hospital Pharmaceutical Market, by Key Players, 2014 (Value %)
FIG. 9 Global Hospital Pharmaceuticals Market, Cardiology Segmentation 
FIG. 10 Global Cardiology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 11 Global Hospital Pharmaceuticals Market, Oncology Segmentation 
FIG. 12 Global Oncology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 13 Global Hospital Pharmaceuticals Market, Nephrology and Urology segmentation
FIG. 14 Global Nephrology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 15 Global Hospital Pharmaceuticals Market, Neurology Segmentation
FIG. 16 Global Neurology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 17 Global Hospital Pharmaceuticals Market, Pain Segmentation 
FIG. 18 Global Pain Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 19 Global Hospital Pharmaceuticals Market, Infection Segmentation
FIG. 20 Global Infection Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 21 Global Hospital Pharmaceuticals Market, segmentation by Indication
FIG. 22 Global Cardiology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 23 Global Oncology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 24 Global Nephrology and Urology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 25 Global Neurology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 26 Global Pain Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 27 Global Infection Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 28 Comparative Analysis: Global Hospital Pharmaceuticals Market Revenue, by Geography (Value %), 2014 & 2023
FIG. 29 North America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 30 Europe Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 31 Asia Pacific Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 32 Latin America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 33 Rest of the World Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 34 AstraZeneca plc: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 35 Bayer AG Annual Revenue: 2012 – 2014 (US$ Million)
FIG. 36 Bristol-Myers Squibb Company: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 37 Eli Lilly and Company: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 38 GlaxoSmithKline plc: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 39 Johnson & Johnson: Annual Revenue, 2012– 2014 (US$ Million)
FIG. 40 Merck & Co., Inc.: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 41 Novartis AG Annual Revenue: 2012 – 2014 (US$ Million)
FIG. 42 Pfizer, Inc.: Annual Revenue 2012 – 2014 (US$ Million)
FIG. 43 Sanofi: Annual Revenue, 2012 – 2014 (US$ Million)

 

List of Tables

TABLE 1 Market Snapshot: Global Hospital Pharmaceuticals Market
TABLE 2 Major Patent Expirations in Forecast Period
TABLE 3 Event Impact Analysis: Hospital Pharmaceutical Market
TABLE 4 Global Hospital Pharmaceuticals Market Revenue, by Major Therapeutic Areas, 2013-2023 (US$ Million)
TABLE 5 Cardiology Pipeline Overview
TABLE 6 Oncology Pipeline Overview
TABLE 7 Nephrology and Urology Pipeline Overview
TABLE 8 Neurology Pipeline Overview
TABLE 9 Pain Pipeline Overview
TABLE 10 Infection Pipeline Overview
TABLE 11 Global Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
TABLE 12 Global Hospital Pharmaceuticals Market Revenue, by Geography, (US$ Mn), 2013-2023

Hospital pharmaceuticals are medications and drugs administered to patients in hospital settings that include both inpatient and outpatient treatment. Drugs under hospital pharmaceuticals range from paracetamol used to ease pain and minor aches to prescription drugs prescribed for several chronic diseases such as blood pressure, diabetes, and cancer. The hospital pharmaceuticals market has been largely affected due to the economic slowdown and expiration of patents for major blockbuster as well as branded drugs. However, increasing prevalence of diseases, affordability, rising awareness, and health care spending are some of the factors driving the hospital pharmaceuticals market in emerging economies in Asia Pacific and Rest of the World. The global hospital pharmaceuticals market was valued at US$ 197.3 Bn in 2014 and is estimated to reach US$ 280.3 Bn by 2023, expanding at a CAGR of 3.9% during the forecast period from 2015 to 2023.

The global hospital pharmaceuticals market has been studied from two perspectives: therapeutic class and indications. Based on therapeutic class, the hospitals pharmaceuticals market has been segmented into cardiology, oncology, neurology, pain, and infection. The cardiology therapeutic area has been divided further into dyslipidemia drugs, antihypertensive drugs, and others (anti-coagulants and anti-arrhythmic drugs). The oncology segment accounted for the largest share of over 35% of the hospital pharmaceuticals market in 2014. Moreover, this segment is expected to register the highest growth rate during the forecast period from 2015 to 2023. Immunomodulating agents was the largest sub-segment of the oncology segment in 2014. However, alkylating agents is likely to be the fastest growing segment during the forecast period from 2015 to 2023 due to their ability to demonstrate activity against cancer cells during every phase of its life cycle.

The market for hospital pharmaceuticals by indications is sub-segmented into cardiology, oncology, nephrology and urology, neurology, pain and infection. Each of the aforementioned indications is further studied on the basis of the prominently occurring diseases. For instance, the market for cardiology is further categorized into stroke, high blood pressure, heart failure and other cardiovascular diseases such as arrhythmia and cardiomyopathy. Similarly the oncology therapeutic segment is further studied for lung cancer, breast cancer, colorectal cancer, prostate cancer, and others (esophageal, stomach and liver cancer). Other indications have been segmented following a similar protocol. In terms of indication, prostate cancer was the largest segment of the hospital pharmaceuticals market in terms of revenue in 2014. According to the World Cancer Research Fund International, over 1.1 million cases of prostate cancer were recorded in 2012, accounting for around 8% of all new cancer cases and 15% of all cancers diagnosed in men. Increasing incidence of the disease is likely to lead to rise in demand for prostate cancer drugs.

Geographically, this market has been segmented into North America, Europe, Asia-Pacific, Latin America, and Rest of the World (RoW). These have been further categorized into major countries. North America dominated the global hospital pharmaceuticals market due to high R&D activities, favorable reimbursement policies, and availability of advanced health care infrastructure. Asia Pacific and Latin America constitute the key emerging markets for hospital pharmaceuticals due to rise in incidence of chronic diseases such as cardiovascular disease and cancer. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East, and Latin America is likely to boost the hospital pharmaceuticals market. Several multinational pharmaceutical companies are now looking toward the ‘pharmerging’ economies in Asia-Pacific due to their large population base, increasing disposable income, and an aging population suffering from various chronic and acute diseases.

 Major players in the market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., and Sanofi-Aventis.

hospital-pharmaceuticals-2016-market

 


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries